ILNS News 0.0073 05/01/2014 05:08:35 Intellect Neuroscien (I

New Post Public Reply Private Reply Replies (0) Message Board

May 1, 2014 at 6:08 AM

Intellect Neuroscien (ILNS) 0.0073 $ILNS

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying
GlobeNewswire - Thu Jan 16, 2:19AM CST
via PRWEB - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates
GlobeNewswire - Thu Nov 14, 1:15PM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is in relation to TOC-1, a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates which are important pathological components in Alzheimer's disease (AD) and other neurodegenerative tauopathies. Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University.

OTC Daily Alert Stock Watch - Intellect Neurosciences, Inc. (OTCQB:ILNS)
WorldStockWire - Tue Aug 13, 6:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Intellect Neurosciences Retains Chain Pharmaceuticals LLC
GlobeNewswire - Tue Jul 30, 10:30AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.

Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Thu Jun 20, 8:25AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Elliot Maza, a member of the Board of Directors of the company.

NY biotech financier gets prison for stock scheme
By LARRY NEUMEISTER - AP - Thu May 02, 7:35PM CDT
NEW YORK (AP) — A federal judge displayed anger as she handed down a four-year prison sentence Thursday to a biotechnology financier who was once among the nation's wealthiest people.

Intellect Neurosciences Issues Letter to Shareholders
GlobeNewswire - Fri Mar 29, 8:35AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
GlobeNewswire - Thu Feb 28, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.

Market Maker Surveillance Report. DVAX, FCX, PSSI, CIM, S, ILNS, Highest Net Sell Volume and Negative Price Friction For Tuesday, February 19th 2013
M2 - Wed Feb 20, 2:23AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3840 companies with "abnormal" market making, 3574 companies with positive Friction Factors and 2220 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dynavax Technologies Corp (NASDAQ

VAX), Freeport-McMoRan Copper & Gold Inc (NYSE:FCX), PSS World Medical Inc (NASDAQ

SSI), Chimera Investment Corp (NYSE:CIM), Sprint Nextel Corp (NYSE:S), INTELLECT NEUROSCIENCES INC (OTC:ILNS). To access Friction Factor, Naked

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody
GlobeNewswire - Thu Feb 07, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials
Marketwire - Wed Jan 30, 7:08AM CST
During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.

Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
GlobeNewswire - Wed Jan 02, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12 Alzheimer's Drug Development Summit in Neurotech Insights magazine. Dr. Chain was a Distinguished Speaker at the conference.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FOX News Sweeps 2026 Midterms Coverage Ratings

FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...

Edera's New AI Security Strategy: A Game-Changer?

Shaking Up AI Security, Edera-Style In the world of artificial intelligence, there's always a new twist 'round the corner that makes the tech folks tingle—and Edera just served one up piping hot. This time, we're talking about a security revamp that sidesteps the age-old problem of giving AI agents too much rope to hang themselves. Forget about flinging open the keys to...

Custom Antibody Market Eyes $1.13B by 2031 Growth

Examining the Custom Antibody Market's Growth Projections The custom antibody market's been reeling in some serious attention lately. With the muscle to hit $1.13 billion by the end of 2031, this market's not slouching around. We're talking about a 9.5% compound annual growth rate here, folks. Now that's a figure that gives you something to chew over your coffee. What...

Ecovyst Ups Outlook Amid Strong Q3 Results

By Evelyn Baker Updated Nov 5, 2026 Category News Views 115

A Bold Leap Forward Ecovyst, mighty in the sulfuric acid trade, just dropped news hotter than a griddle on a sizzling morning. Sales surged by 51% in Q3 to a solid $308.6 million, credited to smart moves and timely acquisitions. Not just puffery here; these folks are redirecting the narrative and it's showing in the numbers. Imagine a company selling parts of itself to...

Bowling Makes a Strike at Macy's 100th Parade in NYC

Rolling with Tradition: Bowling at Macy's Parade Back in the day, bowling wasn't exactly the sport making headlines. But times, they change. Here we are in the thick of things, witnessing Go Bowling getting its moment in the spotlight during the historic 100th Macy's Thanksgiving Day Parade®. It's not about raking in the dough or hitting some stocks; it’s about...

SM Investments Wins Five Golden Arrows: Governance on Point

Gold Arrows and Golden Standards What’s in a bunch of gold arrows, you might ask? Well, for SM Investments Corporation, those Five Golden Arrows from the Institute of Corporate Directors aren't just shiny trinkets. They're badges of honor, symbols of a rock-solid governance fortress. For the third year running, they’ve nailed the top spot under the corporate...

WIC 2026: Global Connectivity and Cyber Futures

Connectivity Takes Center Stage in Wuzhen When you throw 1,800 movers and shakers into a room focused on the future of the internet, sparks are gonna fly. That's exactly what's going down at the 2026 World Internet Conference in Wuzhen, China. Brass tacks: this ain't just another snooze-fest. The theme this year screams significance—'Open Source and Openness, Joined...

Empower Brokerage Draws Talent to North Texas Job Fair

Shakeup at the North Texas Job Fair Slinging insurance ain't everyone's dream gig, but some folks find their calling where money meets meaning. The North Texas Job Fair, already known for its heavy foot traffic, saw a unique player strutting their stuff this year—Empower Brokerage. This family-owned insurance agency wasn't just slinging corporate pitch; they offered a...

HSBC Boosts Tender Offer: Capital Management Maneuver

HSBC Raises Stake in Its Own Game See folks, when HSBC announces it's bumping up the ceiling on buying back its own securities, you know there's a game afoot in the capital management arena. They raised the offering to snag up these $3 billion 6% perpetuals from $1 billion up to a hefty $1.5 billion. It's like they’re saying, 'Hey, let’s tighten the belt and make sure...

Duke Energy's $500K Push Against South Carolina Hunger

A Battle Cry Against Hunger Look, there’s no shortage of firms tossing around cash as PR stunts. But Duke Energy’s latest campaign to tackle hunger in South Carolina right at the root is one effort that seems to echo with a real bang. Coming at us with more than $500,000 in support for nearly 70 organizations across the state, they’re not just talking the talk. This...